Avidity Biosciences Inc

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences Announces Expected Record Date for Spin-Off

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44